Document Detail

FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis.
MedLine Citation:
PMID:  20035640     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Liver biopsy-the gold standard in assessing liver histology-is recommended before all antiviral treatment. However, this procedure may cause complications, is costly, and is limited by sampling errors. Hence, noninvasive tests have been proposed to assess the severity of hepatic fibrosis. We propose a novel noninvasive index for predicting liver fibrosis, named fibro-quotient (FibroQ), and compared the diagnostic accuracies of FibroQ, aspartate aminotransferase (AST)-to-platelet ratio index (APRI), and AST/alanine aminotransferase (ALT) ratio (AAR).
METHODS: This retrospective cohort study included 140 consecutive patients with chronic viral hepatitis who had undergone percutaneous liver biopsy before treatment at the Chang Gung Memorial Hospital, Chiayi from May 2005 through December 2007. The clinical data including sex, age, AST, ALT, platelet count, prothrombin time (PT) international normalized ratio (INR), and the Metavir fibrosis score (F0 to F4) of liver histology were recorded. APRI, AAR, and FibroQ were calculated. Receiver operating characteristic (ROC) curves were constructed to compare the accuracies of these three noninvasive tests in predicting significant fibrosis in patients with chronic viral hepatitis.
RESULTS: FibroQ performed better than APRI, but was equal to AAR, in the prediction of significant fibrosis [area under the receiver operating characteristic curve (AUC): 0.783 vs 0.631 (p = 0.02) and 0.783 vs 0.733 (p = 0.26), respectively] and cirrhosis (AUC: 0.791 vs 0.634 (p = 0.03), and 0.791 vs 0.782 (p= 0.47), respectively). Using FibroQ below the lower cutoff value (0.6) and above the higher cutoff value (1.6), 108 of 140 (77.1%) patients could be identified correctly to have or not have significant fibrosis.
CONCLUSION: FibroQ, a novel noninvasive test, is an useful and easy tool to evaluate liver fibrosis in patients with chronic viral hepatitis and has better accuracy than APRI and is equal to AAR. Further prospective studies are warranted to validate its efficacy.
Yung-Yu Hsieh; Shui-Yi Tung; I-Lin Lee; Kamfai Lee; Chien-Heng Shen; Kuo-Liang Wei; Te-Sheng Chang; Chia-Sheng Chuang; Cheng-Shyong Wu; Yi-Hsiung Lin
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chang Gung medical journal     Volume:  32     ISSN:  2309-835X     ISO Abbreviation:  Chang Gung Med J     Publication Date:    2009 Nov-Dec
Date Detail:
Created Date:  2009-12-28     Completed Date:  2010-03-10     Revised Date:  2013-10-22    
Medline Journal Info:
Nlm Unique ID:  101088034     Medline TA:  Chang Gung Med J     Country:  China (Republic : 1949- )    
Other Details:
Languages:  eng     Pagination:  614-22     Citation Subset:  IM    
Department of Gastroenterolgy and Hepatology, Chang Gung Memorial Hospital at Chiayi, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Cohort Studies
Hepatitis, Chronic / complications*
Hepatitis, Viral, Human / complications*
Liver Cirrhosis / diagnosis*
Middle Aged
ROC Curve
Retrospective Studies
Reg. No./Substance:
EC Aminotransferases; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Uric Acid is not an independent predictor of cardiovascular death in patients with angiographically ...
Next Document:  Risk factors associated with transrectal ultrasound guided prostate needle biopsy in patients with p...